Maxiphoto
- After closing Thursday up ~52% following the U.S. FDA's approval of its bladder cancer drug Zusduri (mitomycin), UroGen Pharma (NASDAQ:URGN) is up ~10% in Friday morning trading.
- Zusduri is approved for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer.
- On Friday, Guggenheim doubled